An­oth­er in­flu­en­tial voice takes Bris­tol-My­ers’ top ex­ecs to task as they scram­ble to shore up the big Cel­gene buy­out

Brad Lon­car is not a big fan of the ex­ec­u­tive teams at ei­ther Bris­tol-My­ers Squibb or Cel­gene.

To­day, as Bris­tol-My­ers scram­bled to win in­vestors’ back­ing, the Lon­car Can­cer Im­munother­a­py ETF out­lined why it would line up with the grow­ing — though still mar­gin­al — op­po­si­tion that has gath­ered around the mega-buy­out since Welling­ton, with 8% of Bris­tol’s shares, said it would be vot­ing against the deal. Lon­car joins the ac­tivists at Star­board Val­ue who have plant­ed their flag with the re­bel­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER